Successful treatment of relapsed infant acute lymphoblastic leukemia with intensive antimetabolite-based chemotherapy

J. C. Barredo, U. Yusuf, M. Abboud, J. Laver

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Purpose. The treatment of infant acute lymphoblastic leukemia (ALL) continues to be a significant challenge for pediatric oncologists due to the high incidence of early relapses. Salvage regimens used to date have met limited success. We describe two cases of relapsed infant ALL who have achieved long-term survival with an intensive antimetabolite-based salvage regimen. Patients and Methods. Two consecutive infants with relapsed ALL presented at our institution and were treated with an antimetabolitebased regimen. Both cases exhibited clinical and biological phenotypes previously associated with infantile ALL. Results. Both patients have achieved prolonged and sustained remissions 48 and 30 months EFS respectively following therapy with intensive antimetabolite-based salvage regimen. Conclusions. An intensive multiagent antimetabolite-based salvage regimen resulted in prolonged EFS in two cases of relapsed infant ALL. Dose intensification was achieved by administering repeated cycles of the same treatment schema using high dose chemotherapy throughout therapy. These infants were spared prophylactic cranial irradiation without a negative impact on outcome. The use of Lasparaginase, timed after high-dose Cytarabine (ARA-C) throughout therapy, might have contributed to their cure.

Original languageEnglish (US)
Pages (from-to)256-259
Number of pages4
JournalMedical and Pediatric Oncology
Issue number4
StatePublished - Aug 19 1997
Externally publishedYes


  • Acute lymphoblastic leukemia
  • Antimetabolites
  • Chemotherapy
  • Infant leukemia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research


Dive into the research topics of 'Successful treatment of relapsed infant acute lymphoblastic leukemia with intensive antimetabolite-based chemotherapy'. Together they form a unique fingerprint.

Cite this